Change in Directors or Principal Officers
31-May-2007
[No pipe-line left to develop? Fed-up with Bell? No Golden Parachute in sight? If he thought there was a chance the company was about to be munched, wouldn't he stay on to be bought out?]
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 29, 2007, Christopher F. Mojcik, M.D., Ph.D., notified Alexion Pharmaceuticals, Inc. that he has elected to resign as Senior Vice President, Clinical Development, effective on or about June 26, 2007. Alexion's Clinical Development group will be headed by Stephen Squinto, Ph.D., Executive Vice President and Head of Research, until a search for a new head of the Clinical Development group is completed.
During his nine years as head of the Clinical Development group, Dr. Mojcik led the design and completion of over 15 clinical trials. In particular, Dr. Mojcik made significant contributions to the successful development and regulatory approval of Soliris™ (eculizumab) for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Dr. Mojcik will be re-establishing his private medical practice. Alexion wishes him well in this and all other endeavors. |
